Take Solutions Limited · NSE:TAKE
Take Solutions — Investor Presentation (March 2018)
34 slides from Take Solutions's investor presentation, March 2018
Slide 1: TAKE Solutions Limited
TAKE Solutions Limited Delivering Domain-intensive Services In Life Sciences March, 2018
Slide 2: At A Glance
At A Glance Leader in IDC Europe HQ: Frankfurt, MarketScape: 15,872 Germany Worldwide Life Major trial operations center in Germany and Science Drug USA HQ: Princeton, NJ sites through Europe Revenue FY18 Safety Services Clinical, Regulatory & Specialists in UK, (INR Mn) Safety consulting and Sweden
Slide 3: TAKE is a preferred partner for Life Sciences Companies
TAKE is a preferred partner for Life Sciences Companies , Improving Efficiency And Driving Better Outcomes Across The Drug Development Value Chain
Slide 4: Life Sciences Drug Development Landscape
Life Sciences Drug Development Landscape Bringing a drug to the market is a complex process involving many time consuming and expensive stages US $1 – 1.5 Billion per Drug! Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval ~ 5 Years ~ 1 Year ~ 7 Ye
Slide 5: Where Do We Come In?
Where Do We Come In? US $1 – 1.5 Billion per Drug! Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval ~ 5 Years ~ 1 Year ~ 7 Years ~ 1.5 Years On Going Basic Research (R&D) Molecule formulation (compound) is identified to combat a disease Clinical T
Slide 6: Life Sciences
As a strategic partner, TAKE Solutions delivers full-service Clinical, Regulatory and Safety services and solutions to the Life Sciences Industry LIFE SCIENCES
Slide 7: Need for Outsourcing in Life Sciences
Need for Outsourcing in Life Sciences A paradigm shift is taking place in Life Sciences R&D R&D Marketing & Clinical Marketing & Clinical Branding Research Branding Research Sponsor Sponsor Company Company Regulatory Regulatory Manufacturing Manufacturing Affairs Outsourced Affairs Safety (PV) Inhou
Slide 8: Life Sciences Outsourcing
Life Sciences Outsourcing An Attractive Growth Opportunity Clinical 6% $27.6 Bn (2017) to $32.9 Bn (2020) CAGR Regulatory 11.5% $2.6 Bn (2017) to $3.7 Bn (2020) CAGR Safety 10.5% $1.8 Bn (2017) to $2.5 Bn (2020) CAGR Life Sciences Outsourcing USD 39.1 Bn (2020) Life Sciences The USD 32 Bn Life Scien
Slide 9: Types of Sponsors
Types of Sponsors Who is Outsourcing? Although Large Innovators account for the majority, Mid / Small Innovators are an equally attractive segment in this space! Generics accounts for 10% The Mid/Small Innovators Large Innovators (Turnover >US$ 5Bn) (Turnover US$ 1-5 Bn) account are responsible for
Slide 10: Why Do Sponsors Choose Us?
Why Do Sponsors Choose Us? Our Unique Formula = Technology Platform Based Services + Knowledge Partner Clinical Regulatory Capabilities Services across Full Operational Capabilities Markets Nets Industry Forums Technology Consulting Experts Across The Globe Innovative Platforms Safety Offering both
Slide 11: We Deliver Results
We Deliver Results 120+ Network Members The only company to host 350+ 4,000+ 120,000+ 10 unique proprietary Clinical Sites Regulatory Trials 1,000+ Submissions Life Sciences industry network forums! BABE & Lab Studies 80,000+ Patients & 300+ 1,500+ Volunteers Safety Majority of FTE Consulting Engage
Slide 12: Our Life Sciences Journey
Our Life Sciences Journey We have built our Clinical, Regulatory and Safety offerings organically … Regulatory Regulatory Clinical Regulatory Capabilities Capabilities Capabilities across across Services Services Markets Services across Markets Nets Markets Nets Consulting Consulting Technology Safe
Slide 13: Our Global Life Sciences Brand
Our Global Life Sciences Brand Today Navitas Life Sciences is TAKE’s Global Go-to-market Brand, with capabilities across Clinical, Regulatory and Safety Clinical Regulatory Services Full Operational Capabilities Nets Industry Forums Technology Consulting Experts Across The Globe Innovative Platforms
Slide 14: High-quality global trials enabled by our proprietary eClinical platform
100+ Innovator and Generics Sponsors We deliver High-quality, global trials 350+ Clinal Trials enabled by our proprietary eClinical platform 1,000+ BA/BE & Lab Studies Conducted Clinical Trials for the Conducted USPTO Patent for “Method for 1st Stem Cell Product in the 7% of All Biosimilars Trials i
Slide 15: Key Clinical Offerings
Key Clinical Offerings For Heads of Clinical Operations, focused Medical on sharing best practice to define Bioavailability & Imaging excellence in delivery of clinical trials Bioequivalence Services Studies Biologics & Biosimilars OneClinical Studies Full Service Our Optimized eClinical and Analyti
Slide 16: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Full-service phase II stem cell therapy study Business Need Results Sponsor required a full- service phase II stem cell 1st stem cell-based study in a rare patient pool biological product with high screen fail rate approved by DCGI “ We Greatly Appreciate the
Slide 17: We help life sciences companies Stay Compliant
Submissions Across 130+ Countries 10,000+ Paper Submissions 46,000+ We help life sciences eCTD companies Stay Compliant 120,000+ Global Regulatory 15,000+ Submissions* Nees 5+ USA, APAC & Unique Technology Submitted Propositions LATAM 8% of Total Regulatory Regulatory Hubs Submissions to USFDA 2012-
Slide 18: Key Regulatory Offerings
Key Regulatory Offerings For Labeling Professionals; focused on the full lifecycle of labeling For Regulatory Information Management (RIM) professionals to develop best practices Regulatory and leading edge solutions for RIM Information Submissions Management & Report with over 150 clients, is a Pub
Slide 19: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Global publishing and submission management for top 5 pharma Results Business Need • Successful delivery of 30% of • Make 45k submissions annually the Client’s global requirement across multiple health • ~30% efficiency gain over authorities baseline • Maintai
Slide 20: Minimize Risks across the product lifecycle
We help life sciences companies Minimize Risks across the product lifecycle 30+ 100+ Years in PV* Member Companies of our PV Networks We have successfully completed 300+ Safety Consulting Engagements *through acquisition of WCI Consulting www.takesolutions.com
Slide 21: Key Safety Offerings
Key Safety Offerings For Heads of Safety of Top 30 Life Sciences companies; invests in thought leadership to help shape future practices Adverse Event For Heads of Information Technology for PV departments, focused Reporting on increasing business value from technology investments Safety Risk For He
Slide 22: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Making a mid-size biotech compliant with latest EU regulation changes Results Business Need • The baseline benefit-risk profile of 200+ products was Upcoming regulatory changes established and is actively necessitated an overhaul of the monitored Safety system
Slide 23: Proud Partners
Small / Mid Clientele Innovators Generics Large Innovators Others Proud Partners across all Segments! 23 www.takesolutions.com
Slide 24: Leadership & Experts
Leadership & Experts Srinivasan H R D V Ravi Vice Chairman & MD Director Srinivasan HR, Founder of TAKE Solutions. He D.V. Ravi, Co-founder of TAKE Solutions. He is also the brings over 3 decades of leadership and has Managing Director of Shriram Capital, a financial services held significant leader
Slide 25: Supply Chain Management
_ SUPPLY CHAIN MANAGEMENT
Slide 26: Our Supply Chain Management Solutions
Our Supply Chain Management Solutions Engineering Sourcing Design & build high Smart global quality products sourcing programs with continuous without the engagement and associated risks extended support and hassles Engineering Services Technology Compliance PIM, e-commerce, Compliance enterprise so
Slide 27: Business Performance
JSINESS ERFORMANCE =
Slide 28: Delivering Growth with Healthy Margins
Delivering Growth with Healthy Margins 18,000 23% 15,872 21% 16,000 20.5% 20.7% 19.5% 19.3% 19% 14,000 18.1% 13,446 EBITDA 17% Margins 12,000 29.5% 10,301 CAGR 15% 10,000 13% 8,000 7,304 Operating 11% Revenue 6,000 9% 4,000 3,065 7% 2,622 2,133 27.1% 2,000 1,494 CAGR EBITDA 5% - 3% FY15 FY16 FY17 FY
Slide 29: Region Wise Breakup
Region Wise Breakup Europe FY18 FY17 FY16 6.5% 7.4% 9.0% APAC FY18 FY17 FY16 Americas 13.4% 13.3% 17.0% FY18 FY17 FY16 80.1% 79.3% 74.0% % - Revenue Contribution 29 www.takesolutions.com
Slide 30: Capitalizing On The Potential For Life Sciences
Capitalizing On The Potential For Life Sciences 12% 18% 23% 29% 39% Life Sciences Revenue Growing by 88% 29.5% 77% 82% (CAGR) every year! 71% 61% 91% Revenue from Life Sciences FY14 FY15 FY16 FY17 FY18 (Q4 FY18) Life Sciences Supply Chain Management 30 www.takesolutions.com
Slide 31: Delivering Consistent Returns
Delivering Consistent Returns 19.1% 17.6% 15.3% 15.2% 14.0% RoNW 12.7% (Return on Net worth) 11.8% 12.5% 12.2% ROCE 10.9% (Return on Capital Employed) FY14 FY15 FY16 FY17* FY18** * - QIP dilution in FY17 ** - Preferential share allotment in FY18 31 www.takesolutions.com
Slide 32: TAKE uses platform-based services to provide 360 Degree Coverage
TAKE uses platform-based services to provide 360 Degree Coverage of the life sciences domain, Increasing Speed To Market and Reducing www.takesolutions.com Cost of drug development 32
Slide 33: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements” concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings), demand for our products and services and other statements of our plan, beliefs, expect
Slide 34: Thank You
THANK YOU www.takesolutions.com